{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:31:44Z","timestamp":1793734304332,"version":"4.6.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Zambon SpA"},{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Zambon SpA"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.neuropharm.2020.108024","type":"journal-article","created":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T12:02:42Z","timestamp":1583236962000},"page":"108024","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Effects of safinamide on the glutamatergic striatal network in experimental Parkinson\u2019s disease"],"prefix":"10.1016","volume":"170","author":[{"given":"Miriam","family":"Sciaccaluga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Mazzocchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guendalina","family":"Bastioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Ghiglieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Cardinale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Mosci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Caccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Keywood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Melloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Padoani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Vailati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Picconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Calabresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Tozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2020.108024_bib1","doi-asserted-by":"crossref","first-page":"17921","DOI":"10.1523\/JNEUROSCI.2664-12.2012","article-title":"Rebalance of striatal NMDA\/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease","volume":"32","author":"Bagetta","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108024_bib2","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.2042-7158.1994.tb03736.x","article-title":"The anticonvulsant Fce-26743 is a selective and short-acting Mao-B inhibitor devoid of inducing properties towards cytochrome-P450 dependent testosterone hydroxylation in mice and rats","volume":"46","author":"Benedetti","year":"1994","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108024_bib3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/mds.25751","article-title":"Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations","volume":"29","author":"Borgohain","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2020.108024_bib4","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/mds.25961","article-title":"Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease","volume":"29","author":"Borgohain","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2020.108024_bib5","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1212\/WNL.67.7_suppl_2.S18","article-title":"Safinamide - from molecular targets to a new anti-Parkinson drug","volume":"67","author":"Caccia","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2020.108024_bib6","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S1474-4422(10)70218-0","article-title":"Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap","volume":"9","author":"Calabresi","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2020.108024_bib7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/brain\/116.2.433","article-title":"Electrophysiology of dopamine-denervated striatal neurons - implications for Parkinsons-disease","volume":"116","author":"Calabresi","year":"1993","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2020.108024_bib8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tins.2007.03.001","article-title":"Dopamine-mediated regulation of corticostriatal synaptic plasticity","volume":"30","author":"Calabresi","year":"2007","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108024_bib9","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/nn.3743","article-title":"Direct and indirect pathways of basal ganglia: a critical reappraisal","volume":"17","author":"Calabresi","year":"2014","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108024_bib10","doi-asserted-by":"crossref","first-page":"S174","DOI":"10.1002\/mds.22792","article-title":"Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson's disease","volume":"25","author":"Carta","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2020.108024_bib11","first-page":"2694","article-title":"L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA","volume":"10","author":"Cenci","year":"1998","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108024_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/0471142301.ns0925s41","article-title":"Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice","author":"Cenci","year":"2007","journal-title":"Curr. Protoc. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108024_bib13","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nature11846","article-title":"Concurrent activation of striatal direct and indirect pathways during action initiation","volume":"494","author":"Cui","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2020.108024_bib14","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ana.25364","article-title":"Levodopa-induced dyskinesia in Parkinson disease: current and evolving concepts","volume":"84","author":"Espay","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2020.108024_bib15","doi-asserted-by":"crossref","first-page":"5316","DOI":"10.1038\/ncomms6316","article-title":"Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia","volume":"5","author":"Fieblinger","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2020.108024_bib16","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1124\/jpet.118.251645","article-title":"Safinamide modulates striatal glutamatergic signaling in a rat model of levodopa-induced dyskinesia","volume":"367","author":"Gardoni","year":"2018","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108024_bib17","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev-neuro-061010-113641","article-title":"Modulation of striatal projection systems by dopamine","volume":"34 34","author":"Gerfen","year":"2011","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108024_bib18","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.nbd.2015.11.022","article-title":"Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: behavioral, molecular, and synaptic mechanisms","volume":"86","author":"Ghiglieri","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2020.108024_bib19","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1093\/brain\/awr158","article-title":"Abnormal bidirectional plasticity-like effects in Parkinson's disease","volume":"134","author":"Huang","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2020.108024_bib20","doi-asserted-by":"crossref","first-page":"4732","DOI":"10.1523\/JNEUROSCI.18-12-04732.1998","article-title":"Plasticity of synapses in the rat neostriatum after unilateral lesion of the nigrostriatal dopaminergic pathway","volume":"18","author":"Ingham","year":"1998","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108024_bib21","doi-asserted-by":"crossref","first-page":"7537","DOI":"10.1523\/JNEUROSCI.1176-08.2008","article-title":"Inversion of dopamine responses in striatal medium spiny neurons and involuntary movements","volume":"28","author":"Liang","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108024_bib22","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3389\/fncel.2015.00245","article-title":"NMDA receptor GluN2A\/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients","volume":"9","author":"Mellone","year":"2015","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108024_bib23","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1124\/jpet.117.245100","article-title":"Safinamide differentially modulates in vivo glutamate and GABA release in the rat Hippocampus and basal ganglia","volume":"364","author":"Morari","year":"2018","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108024_bib24","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40262-016-0449-5","article-title":"Clinical pharmacokinetics and pharmacodynamics of safinamide","volume":"56","author":"Muller","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.neuropharm.2020.108024_bib25","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1471-1931(00)00031-8","article-title":"Levodopa motor complications in Parkinson's disease","volume":"23","author":"Obeso","year":"2000","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108024_bib26","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1523\/JNEUROSCI.15-05-03863.1995","article-title":"Forelimb akinesia in the rat Parkinson model - differential-effects of dopamine agonists and nigral transplants as assessed by a new stepping test","volume":"15","author":"Olsson","year":"1995","journal-title":"J. Neurosci."},{"issue":"7","key":"10.1016\/j.neuropharm.2020.108024_bib27","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1517\/13543784.17.7.1115","article-title":"An expert opinion on safinamide in Parkinson's disease","volume":"17","author":"Onofrj","year":"2008","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.neuropharm.2020.108024_bib41","doi-asserted-by":"crossref","first-page":"14182","DOI":"10.1523\/JNEUROSCI.2149-10.2010","article-title":"Distinct levels of dopamine denervation differentially alter striatal synaptic plasticity and NMDA receptor subunit composition","volume":"20","author":"Paill\u00e9","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108024_bib28","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2005"},{"key":"10.1016\/j.neuropharm.2020.108024_bib29","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nn1040","article-title":"Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia","volume":"6","author":"Picconi","year":"2003","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108024_bib30","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1093\/brain\/awh190","article-title":"Therapeutic doses of L-dopa reverse hypersensitivity of corticostriatal D2-dopamine receptors and glutamatergic overactivity in experimental parkinsonism","volume":"127","author":"Picconi","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2020.108024_bib31","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.nbd.2007.10.001","article-title":"L-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation","volume":"29","author":"Picconi","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2020.108024_bib32","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.nbd.2014.08.002","article-title":"Lack of depotentiation at basal ganglia output neurons in PD patients with levodopa-induced dyskinesia","volume":"71","author":"Prescott","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2020.108024_bib33","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0022-3565(24)38068-1","article-title":"Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound","volume":"288","author":"Salvati","year":"1999","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108024_bib34","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/jamaneurol.2016.4467","article-title":"Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations A randomized clinical trial","volume":"74","author":"Schapira","year":"2017","journal-title":"Jama Neurol."},{"key":"10.1016\/j.neuropharm.2020.108024_bib35","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1152\/jn.00910.2014","article-title":"Dopamine regulates distinctively the activity patterns of striatal output neurons in advanced parkinsonian primates","volume":"113","author":"Singh","year":"2015","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2020.108024_bib36","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1606792113","article-title":"Human striatal recordings reveal abnormal discharge of projection neurons in Parkinson's disease","volume":"113","author":"Singh","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2020.108024_bib37","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.nbd.2017.08.001","article-title":"Rabphilin 3A: a novel target for the treatment of levodopa-induced dyskinesias","volume":"108","author":"Stanic","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2020.108024_bib38","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.conb.2014.07.008","article-title":"Dopaminergic modulation of striatal networks in health and Parkinson's disease","volume":"29","author":"Surmeier","year":"2014","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.neuropharm.2020.108024_bib39","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuroscience.2014.01.042","article-title":"Effect of memantine on L-dopa-induced dyskinesia in the 6-ohda-lesioned rat model of Parkinson's disease","volume":"265","author":"Tronci","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2020.108024_bib40","doi-asserted-by":"crossref","first-page":"6430","DOI":"10.1523\/JNEUROSCI.21-16-06430.2001","article-title":"Cortical slow oscillatory activity is reflected in the membrane potential and spike trains of striatal neurons in rats with chronic nigrostriatal lesions","volume":"21","author":"Tseng","year":"2001","journal-title":"J. Neurosci."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820300903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820300903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T06:59:17Z","timestamp":1758437957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390820300903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":41,"alternative-id":["S0028390820300903"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108024","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of safinamide on the glutamatergic striatal network in experimental Parkinson\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108024"}}